Conflicts of interest at the NIH

Since when is moral and ethical conduct required to be efficient and helpful?

Written byGerald Schneir
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Since when is moral and ethical conduct required to be efficient and helpful? In a recent Opinion,1 the authors express the concept that what is proposed by NIH (after a great deal of foot dragging) is far too stringent and inefficient and not helpful. Fortunately for the public, those writers seem to be implying that those corrupt and unethical scientists are leaving in droves. I hope so. It is these morally challenged individuals who allowed questionable drugs to be brought onto the market, who touted drug therapies at medical meetings that were highly questionable, who profited at the expense of the general public.

If NIH scientists, their families, and their staffs want to invest in the health care industry they have a variety of mutual funds that can do that and avoid any semblance of conflict of interest.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies